
In many ways, the US approval of Boehringer’s Gilotrif for patients with late-stage non-small cell lung cancer (NSCLC) last year …
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer

